2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

4:30PM-6:00PM: Abstract Number: 2822

Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women

5T109: Epidemiology & Public Health III: RA (2822–2827)

4:30PM-6:00PM: Abstract Number: 2818

Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis

5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

4:30PM-6:00PM: Abstract Number: 2836

Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank

5T112: Metabolic & Crystal Arthropathies II: Genetics & Physiology (2834–2839)

4:30PM-6:00PM: Abstract Number: 2810

Does Loss-of-function Variants in SAT1 Cause X-linked Pediatric Lupus?

5T115: SLE – Etiology & Pathogenesis I: Signaling Pathways (2810–2815)

4:30PM-6:00PM: Abstract Number: 2856

Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register

5T116: Spondyloarthritis Including Psoriatic Arthritis – Clinical VI: Psoriatic Arthritis Clinical Studies (2852–2857)

4:30PM-6:00PM: Abstract Number: 2850

Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry

5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

4:30PM-6:00PM: Abstract Number: 2828

Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams

5T111: Measures of Healthcare Quality II: Quality Improvement in Rheumatology – Still Getting Better (2828–2833)

4:30PM-6:00PM: Abstract Number: 2829

Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk

5T111: Measures of Healthcare Quality II: Quality Improvement in Rheumatology – Still Getting Better (2828–2833)

4:30PM-6:00PM: Abstract Number: 2851

Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations

5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

4:30PM-6:00PM: Abstract Number: 2808

Linking Toll-Like Receptor Signaling and Type I Interferons to Inflammation and Fibrosis in a Macrophage/Fibroblast Model of Congenital Heart Block

5T110: Innate Immunity (2804–2809)

4:30PM-6:00PM: Abstract Number: 2815

Lower IL-4R in IgD+ Naïve B Cells Is a Pre-disposing Factor for Development of T-bet+ DN2 B Cells in Systemic Lupus Erythematosus

5T115: SLE – Etiology & Pathogenesis I: Signaling Pathways (2810–2815)

4:30PM-6:00PM: Abstract Number: 2817

Lysosomal Placement of the Energy Sensors AMPK and mTORC1 Controls Tissue Inflammation in Rheumatoid Arthritis

5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

4:30PM-6:00PM: Abstract Number: 2814

Methionine Commits Immunometabolism and Epigenetic Regulation of BACH2 Loci in B Cells, Resulting in Biases Toward Plasmablast Differentiation in the Pathogenesis of SLE

5T115: SLE – Etiology & Pathogenesis I: Signaling Pathways (2810–2815)

4:30PM-6:00PM: Abstract Number: 2805

Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls

5T110: Innate Immunity (2804–2809)

4:30PM-6:00PM: Abstract Number: 2804

Neutrophil Passage Through the Megakaryocyte Cytoplasm via Emperipolesis Modulates Neutrophil Migration

5T110: Innate Immunity (2804–2809)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].